David W. End

1.4k total citations
26 papers, 1.1k citations indexed

About

David W. End is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, David W. End has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in David W. End's work include Retinoids in leukemia and cellular processes (6 papers), Cancer-related Molecular Pathways (6 papers) and Estrogen and related hormone effects (4 papers). David W. End is often cited by papers focused on Retinoids in leukemia and cellular processes (6 papers), Cancer-related Molecular Pathways (6 papers) and Estrogen and related hormone effects (4 papers). David W. End collaborates with scholars based in United States, Cameroon and Hungary. David W. End's co-authors include Gordon Guroff, Geneva Dickens, Judith E. Karp, James R. Wright, Scott H. Kaufmann, Jeffrey E. Lancet, Patrick Angibaud, Marc Venet, Constantine Londos and Kees Bol and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Medicinal Chemistry.

In The Last Decade

David W. End

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David W. End United States 15 631 301 301 133 131 26 1.1k
D End United States 16 744 1.2× 401 1.3× 108 0.4× 161 1.2× 100 0.8× 18 1.2k
Sadao Kuromitsu Japan 19 500 0.8× 214 0.7× 192 0.6× 118 0.9× 92 0.7× 39 1.1k
Bertrand Leblond France 17 665 1.1× 142 0.5× 121 0.4× 259 1.9× 51 0.4× 29 1.2k
J. Paul Secrist United States 18 1.6k 2.5× 525 1.7× 123 0.4× 161 1.2× 65 0.5× 25 2.0k
Penglie Zhang United States 18 350 0.6× 583 1.9× 155 0.5× 108 0.8× 75 0.6× 37 1.2k
Jon Rosen United States 18 460 0.7× 462 1.5× 444 1.5× 98 0.7× 123 0.9× 24 1.6k
Lora B. Kramer United States 22 871 1.4× 298 1.0× 230 0.8× 46 0.3× 98 0.7× 34 1.2k
Hong Chang United States 13 463 0.7× 346 1.1× 51 0.2× 121 0.9× 37 0.3× 18 829
Patrick A. Plé United Kingdom 17 877 1.4× 445 1.5× 124 0.4× 572 4.3× 90 0.7× 30 1.5k
Tim P. Green United Kingdom 13 699 1.1× 504 1.7× 118 0.4× 178 1.3× 71 0.5× 14 1.2k

Countries citing papers authored by David W. End

Since Specialization
Citations

This map shows the geographic impact of David W. End's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. End with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. End more than expected).

Fields of papers citing papers by David W. End

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. End. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. End. The network helps show where David W. End may publish in the future.

Co-authorship network of co-authors of David W. End

This figure shows the co-authorship network connecting the top 25 collaborators of David W. End. A scholar is included among the top collaborators of David W. End based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. End. David W. End is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eichenbaum, Gary, Alfred Tonelli, Edward J. Yurkow, et al.. (2011). Nonclinical Safety Assessment of a Synthetic Peptide Thrombopoietin Agonist. International Journal of Toxicology. 30(4). 385–404. 10 indexed citations
2.
Lu, Tianbao, Shelley K. Ballentine, Edward C. Giardino, et al.. (2010). Discovery and Clinical Evaluation of 1-{N-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif. Journal of Medicinal Chemistry. 53(4). 1843–1856. 27 indexed citations
3.
Angibaud, Patrick, Laurence Mévellec, Christophe Meyer, et al.. (2007). Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra® series. European Journal of Medicinal Chemistry. 42(5). 702–714. 7 indexed citations
4.
5.
Widemann, Brigitte C., Wanda L. Salzer, R.J. Arceci, et al.. (2006). Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas. Journal of Clinical Oncology. 24(3). 507–516. 103 indexed citations
6.
Saha, Ashis & David W. End. (2005). Novel β-(imidazol-4-yl)-β-amino acids: solid-phase synthesis and study of their inhibitory activity against geranylgeranyl protein transferase type I. Bioorganic & Medicinal Chemistry Letters. 15(6). 1713–1719. 3 indexed citations
7.
Angibaud, Patrick, Ashis Saha, David W. End, et al.. (2003). 4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the Farnesyltransferase inhibitor ZARNESTRA ™. Bioorganic & Medicinal Chemistry Letters. 13(24). 4361–4364. 13 indexed citations
8.
Angibaud, Patrick, Ann Devine, David W. End, et al.. (2003). 5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(9). 1543–1547. 27 indexed citations
9.
Angibaud, Patrick, David W. End, Eddy Freyne, et al.. (2003). Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(24). 4365–4369. 19 indexed citations
10.
Venet, Marc, David W. End, & Patrick Angibaud. (2003). Farnesyl Protein Transferase Inhibitor ZARNESTRA™ R115777 - History of a Discovery. Current Topics in Medicinal Chemistry. 3(10). 1095–1102. 58 indexed citations
11.
Karp, Judith E., Scott H. Kaufmann, Alex A. Adjei, et al.. (2001). Current status of clinical trials of farnesyltransferase inhibitors. Current Opinion in Oncology. 13(6). 470–476. 89 indexed citations
12.
Karp, Judith E., Jeffrey E. Lancet, Scott H. Kaufmann, et al.. (2001). Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97(11). 3361–3369. 367 indexed citations
13.
End, David W.. (1999). Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction Pathway. Investigational New Drugs. 17(3). 241–258. 84 indexed citations
14.
Garrabrant, Thomas & David W. End. (1995). A rapid assay for measuring the metabolism of [3H]-retinoic acid in cell cultures. Journal of Pharmacological and Toxicological Methods. 34(4). 219–223. 5 indexed citations
15.
Ho, Chih Y., William Hageman, Richard J. Mohrbacher, & David W. End. (1988). Inhibition of Leukotriene and Thromboxane Biosynthesis by a 9-(4-chlorophenyl) Analogue of Arachidonic Acid. Journal of Pharmaceutical Sciences. 77(2). 149–152. 4 indexed citations
16.
End, David W., et al.. (1983). Identification of nerve growth factor receptors in primary cultures of chick neural crest cells. Developmental Brain Research. 7(2-3). 131–136. 14 indexed citations
17.
18.
End, David W., et al.. (1979). Inhibition of rat brain mitochondrial calcium transport by chlordecone. Toxicology and Applied Pharmacology. 51(1). 189–196. 25 indexed citations
19.
End, David W., et al.. (1977). A comparative study of the disposition of (-)-delta 9-tetrahydrocannabinol in neuroblastoma and glioma cells in tissue culture: relation cellular impairment.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 13(5). 864–71. 11 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D End Breakdown of academic impact, for papers by Sadao Kuromitsu Breakdown of academic impact, for papers by Bertrand Leblond Breakdown of academic impact, for papers by J. Paul Secrist Breakdown of academic impact, for papers by Penglie Zhang Breakdown of academic impact, for papers by Jon Rosen Breakdown of academic impact, for papers by Lora B. Kramer Breakdown of academic impact, for papers by Hong Chang Breakdown of academic impact, for papers by Patrick A. Plé Breakdown of academic impact, for papers by Tim P. Green
Rankless by CCL
2026